Literature DB >> 14696024

EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects.

Benedikt L Amann1, Oliver Pogarell, Roland Mergl, Georg Juckel, Heinz Grunze, Christoph Mulert, Ulrich Hegerl.   

Abstract

In this study the effects of the atypical antipsychotics quetiapine and olanzapine, and the typical antipsychotic haloperidol on EEG patterns were retrospectively investigated in 81 patients under stable monotherapy with either drug (quetiapine: n=22, olanzapine: n=37, haloperidol: n=22). These three subgroups were compared with a control group of healthy subjects (n=30) which were matched regarding sex and age. Diagnoses of patients were schizophrenia (DSM-IV 295.xx, n=61), brief psychotic disorder (DSM-IV 298.8, n=9), schizoaffective disorder (DSM-IV 295.70, n=8) and delusional disorder (DSM-IV 297.1, n=3). There were no statistically significant differences regarding demographic characteristics between the groups. Digital EEG recordings were retrieved from a database and visually assessed by two independent investigators, and one blinded regarding medication. One patient from the quetiapine group (5%), 13 olanzapine patients (35%), five of the haloperidol patients (23%) and two subjects of the control group (7%) had an abnormal EEG. Epileptiform activity was observed in four patients (11%) of the olanzapine group, and none in the others. EEG abnormalities were statistically significantly increased with dose in the olanzapine group, in contrast to patients treated with haloperidol, quetiapine or healthy subjects. In conclusion, EEG abnormalities seem to occur rarely in patients treated with quetiapine comparable to the control group, but significantly more often with haloperidol and olanzapine, possibly due to different receptor profiles of these substances. To our knowledge, this is the first electrophysiological investigation comparing the new atypical antipsychotics quetiapine, haloperidol, olanzapine with healthy subjects. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696024     DOI: 10.1002/hup.537

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  11 in total

Review 1.  Pharmacotherapy of pervasive developmental disorders in children and adolescents.

Authors:  Gabriele Masi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Acute intrathecal baclofen withdrawal: a brief review of treatment options.

Authors:  James C Ross; Aaron M Cook; Gary L Stewart; Brenda G Fahy
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

3.  Enhanced Performance by Interpretable Low-Frequency Electroencephalogram Oscillations in the Machine Learning-Based Diagnosis of Post-traumatic Stress Disorder.

Authors:  Miseon Shim; Chang-Hwan Im; Seung-Hwan Lee; Han-Jeong Hwang
Journal:  Front Neuroinform       Date:  2022-04-26       Impact factor: 3.739

4.  Late-onset seizures associated with quetiapine poisoning.

Authors:  Amy C Young; Kurt C Kleinschmidt; Paul M Wax
Journal:  J Med Toxicol       Date:  2009-03

Review 5.  Tic disorders: from pathophysiology to treatment.

Authors:  Liborio Rampello; Alessandro Alvano; Giuseppe Battaglia; Valeria Bruno; Rocco Raffaele; Francesco Nicoletti
Journal:  J Neurol       Date:  2005-12-05       Impact factor: 6.682

6.  Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study.

Authors:  Nishant Goyal; Samir Kumar Praharaj; Pushpal Desarkar; Haque Nizamie
Journal:  Psychiatry Investig       Date:  2011-12-08       Impact factor: 2.505

7.  EEG alterations during treatment with olanzapine.

Authors:  Detlef Degner; Michael A Nitsche; Frank Bias; Eckart Rüther; Udo Reulbach
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-23       Impact factor: 5.270

8.  Dose-dependent olanzapine-induced myoclonus.

Authors:  Sai Krishna Tikka; Alok Pratap; Vinod Kumar Sinha
Journal:  Toxicol Int       Date:  2014 Sep-Dec

Review 9.  A Framework Proposal to Follow-Up on Preclinical Convulsive Signals of a New Molecular Entity in First-in-Human Studies Using Electroencephalographic Monitoring.

Authors:  Markus Abt; Theo Dinklo; Andreas Rothfuss; Elisabeth Husar; Robert Dannecker; Katja Kallivroussis; Richard Peck; Lucette Doessegger; Christoph Wandel
Journal:  Clin Pharmacol Ther       Date:  2019-05-31       Impact factor: 6.875

10.  Targeting Neural Synchrony Deficits is Sufficient to Improve Cognition in a Schizophrenia-Related Neurodevelopmental Model.

Authors:  Heekyung Lee; Dino Dvorak; André A Fenton
Journal:  Front Psychiatry       Date:  2014-02-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.